Antimuscarinic medication use and risk of glaucoma in patients with overactive bladder: a literature review and disproportionality analysis using individual case safety reports from FAERS.
Sadeghi Hasti H, Lau Rinko R, Omrani Mohammad Ali M, Ahmadi Fatemeh F et al.
This study investigated the potential association between antimuscarinic medications and glaucoma by integrating evidence from a literature review with pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS). A systematic search of MEDLINE and EMBASE through 15 July 2025 identified eight studies, one pooled analysis of two randomized controlled trials, five observational studies, and two case reports that collectively suggested an association between anticholinergic use and increased risk of glaucoma or elevated intraocular pressure. Concurrently, an active-comparator restricted disproportionality analysis of FAERS data (2004Q1-2023Q4) was conducted to compare glaucoma reports among users of oxybutynin, tolterodine, solifenacin, darifenacin, fesoterodine, and trospium versus mirabegron. Adjusted reporting odds ratios (RORs) and information components (IC025) were calculated following READUS-PV guidelines. Compared with mirabegron, antimuscarinics demonstrated a higher reporting rate of glaucoma (adjusted ROR: 3.02; 95% CI: 2.03-4.50; IC025: 0.15), with tolterodine showing the strongest signal (adjusted ROR: 7.67; 95% CI: 4.90-12.02; IC025: 1.24), followed by darifenacin, fesoterodine, and solifenacin. No signals were observed for oxybutynin or trospium. These findings suggest that certain antimuscarinics, particularly tolterodine, darifenacin, and fesoterodine, may be associated with an increased risk of glaucoma and warrant further pharmacoepidemiologic investigation to confirm safety and inform prescribing decisions.